Conditions: Social Anxiety Disorder (SAD)
Interventions: Behavioral: Ai chatbot
Sponsors: Stockholm University
Active, not recruiting
Interventions: Behavioral: Ai chatbot
Sponsors: Stockholm University
Active, not recruiting
Preliminary Efficacy of the AdoptMindful2Care@Web: A Pilot RCT With Adoptive Parents
Conditions: Parenting Stress; Positive Mental Health
Interventions: Behavioral: pAdoptMindful2Care@Web
Sponsors: University of Coimbra
Not yet recruiting
Interventions: Behavioral: pAdoptMindful2Care@Web
Sponsors: University of Coimbra
Not yet recruiting
An inducible base editing platform for cancer functional genomics in vivo
Nature Biotechnology, Published online: 15 April 2026; doi:10.1038/s41587-026-03079-3
We developed a functional genomics platform using a small-molecule-controllable base editor that enables gene editing with reduced cellular toxicity and minimal transcriptional perturbation. The resulting high efficiency of the method potentiates in vivo inducible genetic screening, allowing systematic identification of critical residues in cancer therapeutic targets.
Baseline Mismatch Negativity Amplitude Predicts Direction and Magnitude of Ketamine Effect in Healthy Volunteers — A “Disordinal” Effect
Mismatch negativity (MMN) is a component of the auditory event-related potential (ERP) that is elicited during a passive oddball paradigm where task-irrelevant infrequent deviants are presented in a stream of more frequent standard stimuli. MMN is believed to index a pre-attentive stage of auditory information processing closely linked to N-methyl-D-aspartate receptors (NMDAR) function. Ketamine is thought to act primarily as an NMDAR antagonist, has been used in clinical trials to model the symptoms of schizophrenia and is increasingly used in the clinic to treat depression.
Can psychiatric genetics advance without incorporating a lifecourse perspective?
Psychiatric disorders unfold over the lifecourse, yet genomic studies of these conditions overwhelmingly rely on phenotypes collected at a single time point, often in adulthood. Genome-wide association studies (GWAS) of psychiatric conditions may therefore miss genetic variants with time-varied relevance to etiology, prevention and treatment, such as those that influence trajectories of symptoms and behaviors, age-at-onset, course of treatment response, and co-evolution of comorbidities. With recent advances in longitudinal biobanks and analytic tools, we posit that incorporating a lifecourse perspective in psychiatric genetics will enable critically relevant insights into each of these areas of investigation.
[Comment] Psychonauts: reimagining recovery in forensic psychiatry
Inside a locked forensic ward at the University Psychiatric Hospital Vrapče—Croatia’s oldest and largest psychiatric institution—patients began building a world of their own: one puppet, one frame at a time. Psychonauts, an 8-minute stop-motion film co-created by forensic psychiatric in-patients, started as an unassuming art therapy exercise but gradually evolved into a powerful act of collective authorship. Originating behind secure doors, Psychonauts is now on its own journey, reaching spotlights, being celebrated at prestigious international festivals (including Special Mention at Annecy, 2025, and Best Short at Guanajuato, 2025), currently even in consideration for an Oscar.
[Comment] Youth mental health in central Asia: research needs
Little research has been published on mental health difficulties in young people (aged 10–24 years) living in central Asia,1 a region comprising Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. As researchers and representatives from academic, non-governmental, governmental, and UN organisations working in Kyrgyzstan and Uzbekistan and beyond, we are noting an increasing number of young people reporting emotional and behavioural symptoms in central Asia in published articles2 and from our own observations.
[Comment] Magnetic seizure therapy: balancing efficacy and cognition
Few treatments in psychiatry match the antidepressant efficacy of convulsive therapy. Yet despite this therapeutic potency, persistent stigma and concerns about cognitive adverse effects—particularly autobiographical memory disturbance associated with electroconvulsive therapy, ECT—continue to limit its wider adoption.1 This tension is especially consequential in treatment-resistant depression (TRD), where convulsive therapies remain among the most effective treatments.2
[Editorial] Putting placebo effects in a new light
Placebo effects have puzzled and intrigued researchers for decades but, despite playing an important role in modern trial design and treatment development, they remain relatively mysterious. With the development of new treatments in psychiatry, especially psychedelic-assisted psychotherapy, placebo effects are under the spotlight. In this issue, The Lancet Psychiatry presents two Review articles by Matthew Burke and colleagues on reconceptualising placebo and nocebo effects.
[Comment] Assessing adolescents’ use of artificial intelligence in psychiatric practice
In a recent clinical encounter with one of the authors (AP), a young boy with autism insisted that his mother hated him—because ChatGPT said so. After asking whether a parent who sets limits must dislike their child, he interpreted the bot’s confident, literal response as truth. By the time the boy arrived at the clinic, this exchange had already reshaped his affect, relationships, and risk. Encounters like this are increasingly common, and many adolescents now present with beliefs—and sometimes safety concerns—influenced by generative artificial intelligence (AI).